Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Pharmacovigilance01:19

Pharmacovigilance

2.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

706
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
706
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

861
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
861
Drug Regulation01:25

Drug Regulation

3.0K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.0K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

395
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
395

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gender-Specific Behavior Reductions in Spontaneous Locomotive and Rearing in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy: A Pilot Study.

Journal of pain research·2026
Same author

Change in opioid use following spinal cord stimulation: a systematic review and meta-analysis.

Regional anesthesia and pain medicine·2026
Same author

Gender Disparities in Interventional Pain Medicine: Representation, Leadership, and Compensation.

Pain practice : the official journal of World Institute of Pain·2026
Same author

High-intensity light therapy for post-interventional complications and pain after minimally invasive spinal procedures: a case series.

Lasers in medical science·2026
Same author

Evaluating the risk of methadone and QTc interval prolongation in an oncologic population.

Regional anesthesia and pain medicine·2026
Same author

Prevalence of PD-1 Inhibitor-Associated Peripheral Neuropathy: A Retrospective Cohort Study.

Life (Basel, Switzerland)·2026

Related Experiment Video

Updated: May 2, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.0K

Looming Concerns With Gabapentin Oversight: Balancing Safety and Access.

Saba Javed1, Larry C Driver1, Jay Karri2

  • 1Department of Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Pain Practice : the Official Journal of World Institute of Pain
|April 30, 2026
PubMed
Summary

Gabapentin, a pain medication, is increasingly regulated due to overdose risks, especially with other depressants. This may limit access for patients needing this non-opioid analgesic.

Keywords:
chronic paingabapentinopioidoverdoseregulation

More Related Videos

A High-content Assay for Monitoring AMPA Receptor Trafficking
10:34

A High-content Assay for Monitoring AMPA Receptor Trafficking

Published on: January 28, 2019

9.6K
Transauricular Vagus Nerve Stimulation and Electroencephalographic Assessment in Disorders of Consciousness
04:04

Transauricular Vagus Nerve Stimulation and Electroencephalographic Assessment in Disorders of Consciousness

Published on: July 11, 2025

2.2K

Related Experiment Videos

Last Updated: May 2, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.0K
A High-content Assay for Monitoring AMPA Receptor Trafficking
10:34

A High-content Assay for Monitoring AMPA Receptor Trafficking

Published on: January 28, 2019

9.6K
Transauricular Vagus Nerve Stimulation and Electroencephalographic Assessment in Disorders of Consciousness
04:04

Transauricular Vagus Nerve Stimulation and Electroencephalographic Assessment in Disorders of Consciousness

Published on: July 11, 2025

2.2K

Area of Science:

  • Pharmacology
  • Public Health
  • Pain Management

Background:

  • Gabapentin is a widely prescribed analgesic for neuropathic pain.
  • Emerging data link gabapentin to respiratory depression and overdose deaths, particularly when combined with CNS depressants.
  • Several states are reclassifying gabapentin as a controlled substance.

Purpose of the Study:

  • To evaluate the rationale behind regulating gabapentin.
  • To examine the potential unintended consequences of gabapentin oversight.
  • To propose strategies for reducing misuse while preserving patient access.

Main Methods:

  • Commentary and analysis of existing data and regulatory trends.
  • Evaluation of the impact of controlled substance reclassification.
  • Exploration of potential risks and benefits of regulation.

Main Results:

  • Gabapentin regulation may restrict access to a crucial non-opioid pain reliever.
  • Oversight could inadvertently foster illicit markets for the drug.
  • Vulnerable populations may face greater healthcare access barriers.

Conclusions:

  • Regulation of gabapentin presents a complex balance between mitigating risks and ensuring patient access.
  • Strategies are needed to reduce misuse without compromising legitimate therapeutic use.
  • Maintaining access for patients requiring gabapentin for pain management is critical.